Table 1 Demographic and baseline characteristics of the cohort on the basis of achieved on-treatment blood pressure control

From: Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial

 

Good control (n=1733)

Poor control (n=1268)

P-value

Sex, male

872 (50.3)

636 (50.2)

0.931

Age, years

63.2±10.4

63.4±11.0

0.574

BMI, kg m−2

24.4±3.4

24.7±3.4

0.042

Systolic BP, mm Hg

151.4±10.2

157.3±12.4

<0.001

Diastolic BP, mm Hg

88.1±9.3

89.4±10.2

<0.001

Heart rate, beat per min

74.0±11.0

74.4±11.5

0.320

Previous CV disease

207 (11.9)

168 (13.2)

0.286

Diabetes

204 (11.8)

223 (17.6)

<0.001

Dyslipidemia

702 (40.5)

515 (40.6)

0.953

Current smoking

688 (39.7)

486 (38.3)

0.447

Anti-hypertensive agents

1362 (78.6)

1061 (83.7)

<0.001

 Benidipine

1076 (62.1)

835 (65.9)

0.034

 Other CCB

183 (10.6)

161 (12.7)

0.069

 ARB

142 (8.2)

143 (11.3)

0.004

 ACE inhibitor

36 (2.1)

17 (1.3)

0.130

 BB

56 (3.2)

36 (2.8)

0.538

 Diuretics

13 (0.8)

18 (1.4)

0.073

 α-Blocker

11 (0.6)

6 (0.5)

0.560

Concomitant medication

 Anti-platelets

138 (8.0)

103 (8.1)

0.873

 Lipid-lowering agents

378 (21.8)

261 (20.6)

0.417

Statin

303 (17.5)

203 (16.0)

0.287

 Antidiabetic agents

97 (5.6)

115 (9.1)

<0.001

  1. Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, β-blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CV, cardiovascular.
  2. Data are shown as the number of patients (%) or mean±s.d. Differences in the proportions between the good and poor control groups were analyzed using the χ2-test or unpaired t-test.
Back to article page